Pharmaceutical

Novo Nordisk’s ocedurenone Phase III flop costs company $816m

NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from KBP Biosciences in 2023 as part of a $1.3bn deal.

Jun 28, 2024 - 04:00
Novo Nordisk’s ocedurenone Phase III flop costs company $816m
NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from KBP Biosciences in 2023 as part of a $1.3bn deal.
Read the original article

Tags:

Previous Article

US CDC recommends routine RSV vaccination for older adults

Next Article

FDA issues complete response to Daiichi Sankyo-MSD’s BLA for NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

FibroGen axes 75% of staff after lead cancer therapy fa...

Aug 1, 2024

The Witty Answer to GSK’s Future

The Witty Answer to GSK’s Future

Apr 16, 2023

STAT+: FDA’s letter to medical device maker iRhythm is a warning for the industry

STAT+: FDA’s letter to medical device maker iRhythm is ...

Jun 12, 2023